Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.60 |
| ▸ | MAP2 | P11137 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295661 | 0.92 | MAP2 (0.52) | PDE10AMAP2CA1CA2MEN1 | |
| SCHEMBL6300838 | 0.88 | MEN1 (0.56) | PDE10AMAP2CA1CA2MEN1 | |
| SCHEMBL6295963 | 0.87 | MAP2 (0.47) | PDE10AMAP2CA1CA2MEN1 | |
| SCHEMBL25200113 | 0.86 | MEN1 (0.47) | PDE10AMAP2CA1CA2MEN1 | |
| SCHEMBL6295994 | 0.84 | MAP2 (0.45) | PDE10AMAP2CA1CA2MEN1 | |
| SCHEMBL6294965 | 0.84 | SERPINE1 (0.49) | PDE10AMAP2MEN1KMT2A | |
| SCHEMBL13550372 | 0.84 | KDM4E (0.62) | PDE10AMAP2CA1CA2MEN1 | |
| SCHEMBL25198348 | 0.84 | CCNT1 (0.45) | PDE10AMAP2CA1CA2MEN1 | |
| SCHEMBL6280799 | 0.83 | KDM4E (0.59) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL6295699 | 0.83 | KDM4E (0.59) | MAP2ALDH1A1KDM4EPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897316-B2 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | CHINA MEDICAL UNIVERSITY (TW) | 2005-05-24 | — | — | US | disclosed |
| US-20050032832-A1 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | CHINA MEDICAL UNIVERSITY (TW) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032832-A1 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHUK | PDE10A 3674/4885MAP2 518/4885CA1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.